|
US5820868A
(en)
|
1993-12-09 |
1998-10-13 |
Veterinary Infectious Disease Organization |
Recombinant protein production in bovine adenovirus expression vector system
|
|
IL160406A0
(en)
|
1995-06-15 |
2004-07-25 |
Crucell Holland Bv |
A cell harbouring nucleic acid encoding adenoritus e1a and e1b gene products
|
|
US6783980B2
(en)
|
1995-06-15 |
2004-08-31 |
Crucell Holland B.V. |
Packaging systems for human recombinant adenovirus to be used in gene therapy
|
|
AUPO023496A0
(en)
*
|
1996-05-31 |
1996-06-27 |
Commonwealth Scientific And Industrial Research Organisation |
Modified small RNA viruses
|
|
US6420629B1
(en)
*
|
1996-09-09 |
2002-07-16 |
B.C. Research Inc. |
Process of increasing plant growth and yield and modifying cellulose production in plants
|
|
US7232899B2
(en)
*
|
1996-09-25 |
2007-06-19 |
The Scripps Research Institute |
Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use
|
|
WO1998059063A2
(en)
|
1997-06-23 |
1998-12-30 |
University Of Saskatchewan |
Bovine adenovirus type 3 genome
|
|
FR2770537B1
(fr)
*
|
1997-11-03 |
2001-06-01 |
Commissariat Energie Atomique |
Vecteur peptidique de transfection, composition le contenant et leurs applications
|
|
WO1999036545A2
(en)
*
|
1998-01-16 |
1999-07-22 |
Genzyme Corporation |
Adenoviral vectors with modified capsid proteins
|
|
IL137681A0
(en)
*
|
1998-02-06 |
2001-10-31 |
Uab Research Foundation |
Adenovirus vector containing a heterologous peptide epitope in the hi loop of the fiber knob
|
|
AU751542B2
(en)
*
|
1998-02-17 |
2002-08-22 |
Uab Research Foundation, The |
Modified adenovirus containing a fiber replacement protein
|
|
AU3358999A
(en)
*
|
1998-03-20 |
1999-10-11 |
Genzyme Corporation |
Chimeric adenoviral vectors for targeted gene delivery
|
|
AU4070499A
(en)
|
1998-04-30 |
1999-11-16 |
Cornell Research Foundation Inc. |
Adenoviral vectors with tandem fiber proteins
|
|
US20030017138A1
(en)
|
1998-07-08 |
2003-01-23 |
Menzo Havenga |
Chimeric adenoviruses
|
|
US20040043489A1
(en)
*
|
1998-07-08 |
2004-03-04 |
Menzo Havenga |
Gene delivery vectors provided with a tissue tropism for dendritic cells and methods of use
|
|
US6455314B1
(en)
|
1998-09-11 |
2002-09-24 |
Genvec, Inc. |
Alternatively targeted adenovirus
|
|
US6841540B1
(en)
*
|
1998-09-29 |
2005-01-11 |
The Uab Research Foundation |
Immunomodulation by genetic modification of dendritic cells and B cells
|
|
US6929946B1
(en)
*
|
1998-11-20 |
2005-08-16 |
Crucell Holland B.V. |
Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
|
|
US6649396B1
(en)
*
|
1999-02-05 |
2003-11-18 |
Uab Research Foundation |
Fiber receptor-independent system for the propagation of adenoviral vectors
|
|
ATE540686T1
(de)
*
|
1999-05-12 |
2012-01-15 |
Uab Research Foundation |
Adenovirus mit erhöhter infektiosität und konditionaler replikationsfähigkeit und deren verwendungen
|
|
US6913922B1
(en)
*
|
1999-05-18 |
2005-07-05 |
Crucell Holland B.V. |
Serotype of adenovirus and uses thereof
|
|
US6492169B1
(en)
|
1999-05-18 |
2002-12-10 |
Crucell Holland, B.V. |
Complementing cell lines
|
|
US20050232900A1
(en)
*
|
1999-05-18 |
2005-10-20 |
Crucell Holland B.V. |
Serotype of adenovirus and uses thereof
|
|
WO2003104467A1
(en)
*
|
2002-04-25 |
2003-12-18 |
Crucell Holland B.V. |
Means and methods for the production of adenovirus vectors
|
|
EP1754488A1
(en)
|
1999-05-24 |
2007-02-21 |
Introgen Therapeutics, Inc. |
Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
|
|
WO2001002431A1
(en)
*
|
1999-07-06 |
2001-01-11 |
Got-A-Gene Ab |
Recombinant adenovirus
|
|
EP1214098B1
(en)
*
|
1999-09-24 |
2006-11-22 |
The Uab Research Foundation |
Capsid-modified recombinant adenovirus and methods of use
|
|
US6955808B2
(en)
*
|
1999-09-24 |
2005-10-18 |
Uab Research Foundation |
Capsid-modified recombinant adenovirus and methods of use
|
|
AU1087701A
(en)
*
|
1999-10-15 |
2001-04-30 |
Canji, Inc. |
Targeted vectors
|
|
CA2388337C
(en)
|
1999-10-22 |
2013-01-08 |
Aventis Pasteur Limited |
Method of inducing and/or enhancing an immune response to tumor antigens
|
|
AU3679801A
(en)
|
2000-02-08 |
2001-08-20 |
Rice University |
Optically-active nanoparticles for use in therapeutic and diagnostic methods
|
|
DK1282702T3
(da)
*
|
2000-05-10 |
2007-04-02 |
Sanofi Pasteur Ltd |
Immunogene polypeptider, som er kodet af KAGE-minigener, og anvendelser deraf
|
|
US10293056B1
(en)
|
2000-05-24 |
2019-05-21 |
Board Of Regents, The University Of Texas System |
Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
|
|
EP1157999A1
(en)
*
|
2000-05-24 |
2001-11-28 |
Introgene B.V. |
Methods and means for enhancing skin transplantation using gene delivery vehicles having tropism for primary fibroblasts, as well as other uses thereof
|
|
WO2001092549A2
(en)
*
|
2000-05-31 |
2001-12-06 |
Genvec, Inc. |
Method and composition for targeting an adenoviral vector
|
|
AU6368901A
(en)
|
2000-05-31 |
2001-12-11 |
Univ Saskatchewan |
Modified bovine adenovirus having altered tropism
|
|
US6762031B2
(en)
|
2000-06-16 |
2004-07-13 |
University Of Medicine And Dentistry Of New Jersey |
Targeting viral vectors to specific cells
|
|
US6524572B1
(en)
*
|
2000-06-26 |
2003-02-25 |
Rainbow Therapeutic Company |
Targeting recombinant virus with a bispecific fusion protein ligand in coupling with an antibody to cells for gene therapy
|
|
US20020164333A1
(en)
*
|
2000-07-10 |
2002-11-07 |
The Scripps Research Institute |
Bifunctional molecules and vectors complexed therewith for targeted gene delivery
|
|
CA2421864A1
(en)
*
|
2000-09-20 |
2002-03-28 |
Crucell Holland B.V. |
Transduction of dendritic cells using adenoviral vectors
|
|
DE60138403D1
(de)
|
2000-09-26 |
2009-05-28 |
Crucell Holland Bv |
Adenovirale vektoren für die übertragung von genen in zellen der skelettmuskulatur oder myoblasten
|
|
EP1191104A1
(en)
*
|
2000-09-26 |
2002-03-27 |
Introgene B.V. |
Gene delivery vehicles and use thereof in the preparation of a medicament and/or vaccine
|
|
EP1207205A1
(en)
*
|
2000-11-20 |
2002-05-22 |
Crucell Holland B.V. |
Adenoviral replicons
|
|
AU2002250081A1
(en)
*
|
2001-02-14 |
2002-08-28 |
Uab Research Foundation |
Combined transductional and transcriptional targeting system for improved gene delivery
|
|
US8034791B2
(en)
|
2001-04-06 |
2011-10-11 |
The University Of Chicago |
Activation of Egr-1 promoter by DNA damaging chemotherapeutics
|
|
US20040242523A1
(en)
*
|
2003-03-06 |
2004-12-02 |
Ana-Farber Cancer Institue And The Univiersity Of Chicago |
Chemo-inducible cancer gene therapy
|
|
EP1390476A4
(en)
*
|
2001-04-17 |
2005-03-30 |
Vectorlogics Inc |
MOSAIC adenovirus vectors
|
|
US20060073530A1
(en)
*
|
2001-08-15 |
2006-04-06 |
Olaf Schneewind |
Methods and compositions involving sortase B
|
|
EP1516055A4
(en)
*
|
2002-01-24 |
2007-08-08 |
Scripps Research Inst |
FIBER OPERATING MODIFICATIONS FOR EFFICIENT TARGETS
|
|
WO2003065787A2
(en)
*
|
2002-02-06 |
2003-08-14 |
Johns Hopkins University School Of Medicine |
Methods and compositions for the targeting of a systemic immune response to specific organs or tissues
|
|
ES2290449T3
(es)
|
2002-04-09 |
2008-02-16 |
Sanofi Pasteur Limited |
Acido nucleico de cea modificado y vectores de expresion.
|
|
EP1556082A1
(en)
*
|
2002-10-22 |
2005-07-27 |
Aventis Pasteur Limited |
Anti-cancer vaccines and high-dose cytokines as adjuvants
|
|
US20040166091A1
(en)
|
2003-02-24 |
2004-08-26 |
Genvec, Inc. |
Materials and methods for treating disorders of the ear
|
|
WO2004104032A2
(en)
*
|
2003-05-14 |
2004-12-02 |
The University Of Iowa Research Foundation |
Methods and compositions related to high-titer pseudotyped retroviruses
|
|
WO2005012537A2
(en)
*
|
2003-07-25 |
2005-02-10 |
Genvec, Inc. |
Adenoviral vector-based vaccines
|
|
CA2550583C
(en)
*
|
2003-10-08 |
2013-01-15 |
Sanofi Pasteur, Inc. |
Modified cea /b7 vector
|
|
DE602004025726D1
(de)
*
|
2003-11-14 |
2010-04-08 |
Genvec Inc |
Pharmazeutische verbindung zur behandlung von lokal fortgeschrittenem primär inoperablen pankreaskarzinom (lapc).
|
|
US20080241262A1
(en)
*
|
2004-03-29 |
2008-10-02 |
The University Of Houston System |
Nanoshells and Discrete Polymer-Coated Nanoshells, Methods For Making and Using Same
|
|
AU2005243730B2
(en)
|
2004-04-12 |
2010-05-27 |
Genvec, Inc. |
Method of using adenoviral vectors to induce an immune response
|
|
EP1781284B1
(en)
*
|
2004-08-25 |
2010-10-13 |
The University of Chicago |
Use of the combination comprising temozolomide and tnf-alpha for treating glioblastoma
|
|
EP1784493A2
(en)
*
|
2004-09-01 |
2007-05-16 |
The Government of the United States of America as Represented by The Department of Health and Human Services |
Adenoviral vectors able to transduce apcs, potential use in immune response generation
|
|
AU2005294265A1
(en)
|
2004-10-06 |
2006-04-20 |
University Of Rochester |
Treatment of pulmonary hypertension using an agent that inhibits a tissue factor pathway
|
|
EP1819277A4
(en)
*
|
2004-11-12 |
2010-05-05 |
Ltd Kpe |
NANOTE PARTICLE-MEDIATED ULTRASOUND THERAPY AND DIAGNOSTIC IMAGE DISPLAY
|
|
US8999944B2
(en)
|
2005-01-20 |
2015-04-07 |
University Of Rochester |
Thioredoxin interacting protein (TXNIP) as regulator of vascular function
|
|
BRPI0615400A2
(pt)
*
|
2005-08-31 |
2011-05-17 |
Genvec Inc |
vacinas para malária baseadas em vetor adenoviral
|
|
BRPI0618441B8
(pt)
*
|
2005-11-10 |
2021-07-27 |
Genvec Inc |
vetor adenoviral
|
|
WO2007092944A2
(en)
*
|
2006-02-08 |
2007-08-16 |
Introgen Therapeutics, Inc. |
Compositions and methods involving gene therapy and proteasome modulation
|
|
AU2007234698B2
(en)
*
|
2006-04-07 |
2013-08-01 |
The Board Of Regents Of The University Of Texas System |
Methods and compositions related to adenoassociated virus-phage particles
|
|
US20080248060A1
(en)
*
|
2007-01-09 |
2008-10-09 |
Genvec, Inc. |
Adenoviral vector-based malaria vaccines
|
|
WO2008095168A2
(en)
*
|
2007-02-01 |
2008-08-07 |
University Of Chicago |
Compositions and methods related to a recombinant adenoviral vector that targets il 13 receptors
|
|
WO2010107991A2
(en)
|
2009-03-18 |
2010-09-23 |
Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
Use of ixolaris, a tissue factor inhibitor, for the treatment and prevention of cancer
|
|
CN106390107B
(zh)
|
2009-06-10 |
2019-12-31 |
纽约大学 |
病理tau蛋白的免疫靶向
|
|
US9605844B2
(en)
*
|
2009-09-01 |
2017-03-28 |
Cree, Inc. |
Lighting device with heat dissipation elements
|
|
US20120219583A1
(en)
|
2009-10-16 |
2012-08-30 |
Los Alamos National Security, Llc |
Nucleic acid sequences encoding expandable hiv mosaic proteins
|
|
WO2011057254A2
(en)
|
2009-11-09 |
2011-05-12 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Simian adenoviral vector-based vaccines
|
|
KR20120139672A
(ko)
|
2009-11-09 |
2012-12-27 |
젠벡, 인코포레이티드 |
원숭이 아데노바이러스 벡터의 증식 방법
|
|
WO2012021730A2
(en)
|
2010-08-11 |
2012-02-16 |
Genvec, Inc. |
Respiratory syncytial virus (rsv) vaccine
|
|
WO2012083297A2
(en)
|
2010-12-17 |
2012-06-21 |
Genvec, Inc. |
Adenoviral vectors with modified hexon regions
|
|
WO2012088041A1
(en)
|
2010-12-20 |
2012-06-28 |
Genvec, Inc. |
Adenoviral vector-based dengue fever vaccine
|
|
WO2012092341A1
(en)
|
2010-12-28 |
2012-07-05 |
University Of Rochester |
Methods of modifying insulin signaling using biliverdin reductase (bvr) and bvr derived peptides
|
|
LT2753346T
(lt)
|
2011-09-07 |
2020-08-10 |
Mount Sinai School Of Medicine |
Ceramidazė ir ląstelių diferenciacija
|
|
WO2013181128A1
(en)
|
2012-05-29 |
2013-12-05 |
Genvec, Inc. |
Modified serotype 28 adenoviral vectors
|
|
WO2014063155A1
(en)
|
2012-10-21 |
2014-04-24 |
University Of Rochester |
Thy1 (cd90) as a novel therapy to control adipose tissue accumulation
|
|
EP2992112B1
(en)
|
2013-04-22 |
2020-06-03 |
Icahn School of Medicine at Mount Sinai |
Mutations in pdgfrb and notch3 as causes of autosomal dominant infantile myofibromatosis
|
|
TWI710635B
(zh)
|
2014-10-09 |
2020-11-21 |
美商珍維克公司 |
編碼人類無調同源物-1(hath1)之腺病毒載體
|
|
EP3371211B1
(en)
|
2015-11-04 |
2025-01-01 |
Icahn School of Medicine at Mount Sinai |
Rho-associated protein kinase ("rock") inhibitor for treating tumors and cancer, and identifying candidate subjects for such treatment
|
|
JP7466271B2
(ja)
|
2016-03-31 |
2024-04-12 |
ザ ヨーロピアン モレキュラー バイオロジー ラボラトリー |
アデノウイルスコートタンパク質由来送達賦形剤
|
|
WO2017189730A1
(en)
|
2016-04-26 |
2017-11-02 |
Icahn School Of Medicine At Mount Sinai |
Treatment of hippo pathway mutant tumors and methods of identifying subjects as candidates for treatment
|
|
WO2018064523A1
(en)
|
2016-09-30 |
2018-04-05 |
Genvec, Inc. |
Adenovectors for delivery of therapeutic genetic material into t cells
|
|
CA3276112A1
(en)
|
2017-11-04 |
2025-10-30 |
Sona Nanotech Inc. |
Metal nanoparticles and methods of making same
|
|
EP3927833A4
(en)
|
2019-02-21 |
2022-11-30 |
Unleash Immuno Oncolytics, Inc. |
ONCOLYTIC ADENOVIRAL VECTOR AND METHODS OF USE
|
|
CN118767143A
(zh)
|
2019-12-12 |
2024-10-15 |
听治疗有限责任公司 |
用于预防和治疗听力损失的组合物和方法
|
|
WO2024233783A1
(en)
|
2023-05-09 |
2024-11-14 |
Cornell University |
Expression cassette coding for vascular endothelial growth factor
|